製品番号: HY-19829

Sandramycin

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 100940-65-6
分子式: C₆₀H₇₆N₁₂O₁₆
分子量:1221.32

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Sandramycin 構造式

CAS 番号: 100940-65-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

Traditional Cytotoxic Agents

ADC Payloads アイソフォーム固有の製品をすべて表示 :

Antibiotic アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	8 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma) The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)	10.1016/S0960-894X(97)00129-7
B16	IC₅₀	0.4 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma) The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)	10.1016/S0960-894X(97)00129-7
BT-549	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma) The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)	10.1016/S0960-894X(97)00129-7
EBC-1	IC₅₀	1.4 nM Compound: Sandramycin	Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
H322	IC₅₀	20 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma) The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)	10.1016/S0960-894X(97)00129-7
HL-60	IC₅₀	80 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia) The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)	10.1016/S0960-894X(97)00129-7
HT-29	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma) The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)	10.1016/S0960-894X(97)00129-7
IGROV-1	IC₅₀	1.6 nM Compound: Sandramycin	Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
L1210	IC₅₀	0.02 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia) The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)	10.1016/S0960-894X(97)00129-7
MCF7	IC₅₀	300 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma) The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)	10.1016/S0960-894X(97)00129-7
MOLT-4	IC₅₀	0.7 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia) The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)	10.1016/S0960-894X(97)00129-7
OVCAR-3	IC₅₀	1 nM Compound: Sandramycin	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
OVCAR-3	IC₅₀	4 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma) The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)	10.1016/S0960-894X(97)00129-7
PC-3	IC₅₀	0.2 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma) The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)	10.1016/S0960-894X(97)00129-7
SiHa	IC₅₀	0.3 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma) The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)	10.1016/S0960-894X(97)00129-7
SK-MEL-28	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma) The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)	10.1016/S0960-894X(97)00129-7
UCLA P-3	IC₅₀	10 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma) The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)	10.1016/S0960-894X(97)00129-7

体外実験

Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec⁺) A22508-2, B. subtilis (Rec^-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively^[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC₅₀ values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CDF1 female mice injected with leukemia P388 cells^[1]
Dosage:

0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg
Administration:

Intraperitoneal injection; daily; for 5 days
Result:

Was moderately active in vivo against leukemia P388 in mice.

化学情報

CAS 番号 100940-65-6
分子量 1221.32
分子式 C₆₀H₇₆N₁₂O₁₆
SMILES

CC(C)[C@@H](C(OC[C@@H](NC(C1=C(O)C=C(C=CC=C2)C2=N1)=O)C3=O)=O)N(C)C(CN(C)C(CNC([C@@H]4CCCCN4C([C@@H](COC([C@H](C(C)C)N(C)C(CN(C)C(CNC([C@H]5N3CCCC5)=O)=O)=O)=O)NC(C6=C(O)C=C(C=CC=C7)C7=N6)=O)=O)=O)=O)=O
Structure Classification
- Antibiotics
- Other Antibiotics
Initial Source
- Microorganisms
Nocardioides sp.
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. J A Matson, et al. Sandramycin, a Novel Antitumor Antibiotic Produced by a Nocardioides Sp. Production, Isolation, Characterization and Biological Properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7. [Content Brief]

[2]. Katsushi Katayama, et al. Total Synthesis of Sandramycin and Its Analogues via a Multicomponent Assemblage. Org Lett. 2014 Jan 17;16(2):428-31. [Content Brief]

[3]. D L Boger, et al. DNA Binding Properties of Key Sandramycin Analogues: Systematic Examination of the Intercalation Chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Sandramycin

ADC Payloads アイソフォーム固有の製品をすべて表示

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Sandramycin 関連分類

HY-19829 関連分類